Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 12/20 | 0.37 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.36 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18940397 | 0.88 | CDK5 (0.36) | TAS2R8P2RY14RIPK1CDK5CDK5R1 | |
| SCHEMBL18961401 | 0.88 | CDK5 (0.34) | TAS2R8P2RY14RIPK1CDK5CDK5R1 | |
| SCHEMBL18940423 | 0.88 | RIPK1 (0.36) | TAS2R8P2RY14RIPK1CDK5CDK5R1 | |
| SCHEMBL18940377 | 0.86 | CDK5 (0.33) | TAS2R8P2RY14RIPK1CDK5CDK5R1 | |
| SCHEMBL18961335 | 0.85 | TAS2R8 (0.35) | TAS2R8P2RY14RIPK1CDK5CDK5R1 | |
| SCHEMBL18940435 | 0.84 | TAS2R8 (0.36) | TAS2R8P2RY14RIPK1CDK5CDK5R1 | |
| SCHEMBL18961381 | 0.83 | CDK5 (0.42) | TAS2R8RIPK1CDK5CDK5R1 | |
| SCHEMBL18940440 | 0.82 | TAS2R8 (0.38) | TAS2R8P2RY14RIPK1CDK5CDK5R1 | |
| SCHEMBL18940363 | 0.81 | KDM4C (0.48) | P2RY14RIPK1 | |
| SCHEMBL18961340 | 0.81 | TAS2R8 (0.35) | TAS2R8P2RY14RIPK1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922386-B | 1, 4-disubstituted imidazole derivatives | 大日本住友制药株式会社 | 2021-04-02 | — | — | CN | claimed |
| US-10807945-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-10-20 | — | — | US | claimed |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2020-08-27 | — | — | US | claimed |
| EP-3560494-A1 | DRUG TARGETING CANCER STEM CELL | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | claimed |
| EP-3312170-A1 | 1,4-DI-SUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-04-25 | — | — | EP | claimed |
| US-9828362-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | claimed |
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2017-06-15 | — | — | US | claimed |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-05-30 | — | — | US | disclosed |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-06 | — | — | US | disclosed |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | Sumitomo Pharma Co., Ltd. (JP) | 2022-09-06 | — | — | US | disclosed |
| US-20210171440-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3312170-A1 | 1,4-DI-SUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2018-04-25 | — | — | EP | disclosed |
| US-9828362-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9828362-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-9828362-B2 | 1,4-disubstituted imidazole derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-11-28 | — | — | US | disclosed |
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166552-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | NR4A3, NR0B1, NR2C2 | TAS2R8 1436/4885P2RY14 3931/4885RIPK1 3318/4885 |
| US-11434472-B2 | Agent for removing undifferentiated iPS cells | SALL4, NR4A2, NES | TAS2R8 2868/4885P2RY14 2413/4885RIPK1 3612/4885 |
| US-20210171440-A1 | 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE | NR4A3, NR0B1, NR2C2 | TAS2R8 1436/4885P2RY14 3931/4885RIPK1 3318/4885 |
| US-11661397-B2 | 1,4-disubstituted imidazole derivative | NR4A3, NR0B1, NR2C2 | TAS2R8 1436/4885P2RY14 3931/4885RIPK1 3318/4885 |
| US-20200268728-A1 | DRUG TARGETING CANCER STEM CELL | NR5A1, NR3C1, NR3C2 | TAS2R8 2778/4885P2RY14 3207/4885RIPK1 2464/4885 |
| US-10807945-B2 | 1,4-disubstituted imidazole derivative | NR0B1, NR4A3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TAS2R8 1920/4885P2RY14 3845/4885RIPK1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.